Trial Profile
An Open-Label, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and the Antiviral Activity of NM283 When Administered Alone and in Combination With Pegylated Interferon Alfa 2b to Treatment-Naive Adults With Genotype-1 Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Valopicitabine (Primary) ; Peginterferon alfa-2b
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 24 Oct 2006 New trial record.